Alzheimer's disease

Where the papers sit

26 papers from the last 6 months study alzheimer's disease directly · updated from PubMed 10 Oct 2026

• Microglia and Amyloid Pathology

  Microglial state, amyloid beta and lysosomal dysfunction remain the central links between inflammation and neuronal injury. Extracellular vesicles, celastrol, ribavirin and manganese-oxide nanocomposites are being used to reprogram microglia, restore lysosomal function or suppress the integrated stress response. Transcriptomic and metabolomic signatures seek diagnostic markers, while cholinesterase inhibitors add symptomatic and neuroprotective strategies. The field is moving toward mechanism-linked combination therapies, but most evidence remains preclinical and model-dependent.

  9 papers · 34.6%

• Metabolic Links to Dementia

  Insulin resistance and type 2 diabetes are being linked to dementia through shared genetic signals and prospective risk estimates. Antidiabetic medication studies ask whether treatment changes cognitive-disorder risk, while Lewy body and Alzheimer biomarkers sharpen diagnostic stratification. Metabolomic platforms are adding serum signatures to this clinical picture. The stimulation protocol is exploratory, so evidence still favors risk characterization over a settled metabolic intervention.

  6 papers · 23.1%

• Alzheimer's Care and Treatment

  Alzheimer's care is expanding beyond standard drug treatment to culturally tailored music therapy, complementary compounds and drug repurposing. Anti-herpetic exposure is being tested as a possible modifier of later treatment initiation, while Majoon-e-Boolis and Schisandra remain preclinical or mechanistic. Automated analysis of bio-electrical signals aims to improve biomarker discovery. The approaches share a therapeutic and diagnostic goal but not a convergent clinical direction.

  6 papers · 23.1%

• Cross-Disease Neurodegeneration

  Neurodegenerative disease is being studied across diagnoses and clinical contexts rather than in isolation. Shared microglial transcriptional programs and SPP1 provide a cross-disease biomarker lead, while cohort work links neurodegeneration to biological aging, cardiovascular disease and mortality. Sequencing and localized feature selection support finer-grained risk discovery, with cancer-treatment cohorts adding treatment-related dementia questions. The set is converging on comparative biomarkers and risk stratification, but mechanisms and clinical implications remain open.

  5 papers · 19.2%